NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Clinical Trials
6
Data completeness
2/8 — Basic
PANTOPRAZOLE SODIUM (pantoprazole sodium) by Entera Bio is 12.
Drug data last refreshed 2h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pantoprazole sodium is a proton pump inhibitor (PPI) that suppresses gastric acid production by covalently binding to the (H, K)-ATPase enzyme on gastric parietal cells. It is used to treat gastroesophageal reflux disease (GERD) and erosive esophagitis by inhibiting both basal and stimulated acid secretion with effects persisting beyond 24 hours. The injectable formulation represents an alternative delivery route for patients unable to take oral PPIs.
Pre-Launch
Pre-launch stage suggests early commercial infrastructure building; small team currently focused on regulatory strategy and launch preparation.
Mechanism of Action
12.1 Mechanism of Action Pantoprazole is a PPI that suppresses the final step in gastric acid production by covalently binding to the (H, K)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid…
Worked on PANTOPRAZOLE SODIUM at Entera Bio? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.